Consensus CONMED Corporation Deutsche Boerse AG

Stocks

EC8

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG 01:25:01 10/09/2026 am IST			5-day change	1st Jan Change
40.20 ^EUR	+0.50%		-5.19%	+14.86%

30/07	CONMED Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Raised	MT
30/07	CONMED Corporation, Q2 2026 Earnings Call, Jul 29, 2026

225d805ba9a68eee4.kM8IMoka3hOTvSlE_y8C7EDpiSQQtFu3VGD8xuYjcQo.-KRwRM5etSPm-XkPm0B3mi-oxHtP1QLgFyap8qVaJGL8qmMGuiqZW_WIHQ~9819b95383457f9a77f0fd42e7a42458

Analysts' recommendations: CONMED Corporation

09/07	BMO Capital Initiates CONMED at Market Perform With $36 Price Target	MT
29/06	CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says	MT
29/06	BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target	MT
18/05	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
17/03	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
12/25/12	Conmed Shares Fall After Needham Downgrade	MT
12/25/12	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
28/25/28	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
06/25/06	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
01/24/01	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
25/24/25	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
25/24/25	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
25/24/25	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
01/24/01	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
01/24/01	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
27/23/27	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
26/23/26	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
27/23/27	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
27/23/27	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
05/23/05	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
22/23/22	CL King Starts CONMED at Buy With $140 Price Target	MT
27/23/27	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
27/23/27	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
27/23/27	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
27/23/27	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+13.92%
	MEDTRONIC PLC					+13.39%
	CENCORA, INC.					+13.74%
	HOYA CORPORATION					+31.19%
	BECTON, DICKINSON AND COMPANY					+9.25%
	DEXCOM, INC.					+11.35%
	MEDLINE INC.					+28.57%
	WEST PHARMACEUTICAL SERVICES, INC.					+19.83%
	TERUMO CORPORATION					+35%
	Average					+19.58%
	Weighted average by Cap.					+16.63%